Scientific Abstracts 2 groups (41and 92 pts who achieved RR and didn't respectively). After 2 yrs the factors associated with RR achievement in pts with RA while non-biological DMARDs using were assessed. Results: Before study, pts in both groups were comparable by all demographic, clinical and X-ray characteristics, frequency of DMARDs prescribed. They differed only in frequency of RF-positivity (39.0 and 57.6% respectively in pts achieved RR and didn't, p<0.05), aCCP-positivity (21.7 and 73.3% respectively, p<0.001) and aCCP level (6.06±0.88 and 105.3±22.7 U/ml respectively, p<0.001). There was strong and moderate positive correlation between RR achivement and aCCP-negativity (r=0.57, p<0.05), low aCCP level (r=0.45, p<0.05) and DAS28 (r=0.35, p<0.05). Results of multinomial logistic regression analyses (SPSS, V.22, IBM) showed that RF-negativity was the only independent predictor of RR achievement (B=3.14, p<0.05). 41.7% pts in RR achieved clinical remission by DAS28 as well. Only 19.7% pts achieved clinical remission without RR (p<0.05 vs pts achieved clinical and RR) and 12.5% pts achieved RR without clinical response (DAS28>5.1, DAS28≤1.2 or any value of DAS28 with DAS28≤0.6; p<0.01). After 2 years of treatment the mean value of DAS28 in comparison groups (with and without RR) did not differ (2.79±0.28 vs 2.33±0.17 respectively) so there was a discrepancy between clinical and radiological outcome. Conclusions: Baseline predictors associated with achieving of radiographic remission in pts with RA are RF-and aCCP-negativity, low level of aCCP, but independent predictor of radiographic remission achievement is the only RF-negativity. The discrepancy between the frequency of clinical and radiographic remission achievement in RA patients is observed. Background: In patients with RA in remission subclinical ultrasonographic (US) synovitis (-S) relates to flare and radiographic progression. The impact of tenosynovitis (-T) on flare, disability and radiographic progression is not known. Objectives: To evaluate the predictive role of US-detected tenosynovitis and synovitis in RA patients in remission on flare, disability and radiographic progression over 12-months. Methods: STARTER is a multicentre cohort study of the US Study Group of the Italian Society for Rheumatology. Participants were selected on the basis of a reliability exercise and the availability of high-end equipment with high frequencies probes. Patients with RA in remission underwent clinical and US evaluation. US -T and -S were assessed categorically by Grey Scale (GS) and power Doppler (PD) at 11 joints, extensor and flexor tendons in both hands. Patients were assesed at baseline, 6 and 12 months. The primary outcome was flare within 12 months (defined as increase in DAS28>1.2 or >0.6 if final DAS28>3.2). The secondary outcomes were progression of disability (increase ≥2.3 in the Health Assessment Questionnaire (HAQ)) and radiographic progression (increase in the total Sharp van Der Hejide score (SHS) ≥4.3) at 12 months. Logistic models were used to
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Background: In patients with RA in remission subclinical ultrasonographic (US) synovitis (-S) relates to flare and radiographic progression. The impact of tenosynovitis (-T) on flare, disability and radiographic progression is not known. Objectives: To evaluate the predictive role of US-detected tenosynovitis and synovitis in RA patients in remission on flare, disability and radiographic progression over 12-months. Methods: STARTER is a multicentre cohort study of the US Study Group of the Italian Society for Rheumatology. Participants were selected on the basis of a reliability exercise and the availability of high-end equipment with high frequencies probes. Patients with RA in remission underwent clinical and US evaluation. US -T and -S were assessed categorically by Grey Scale (GS) and power Doppler (PD) at 11 joints, extensor and flexor tendons in both hands. Patients were assesed at baseline, 6 and 12 months. The primary outcome was flare within 12 months (defined as increase in DAS28>1.2 or >0.6 if final DAS28>3.2). The secondary outcomes were progression of disability (increase ≥2.3 in the Health Assessment Questionnaire (HAQ)) and radiographic progression (increase in the total Sharp van Der Hejide score (SHS) ≥4.3) at 12 months. Logistic models were used to measure the relationship between GS-T/-S, PD-T/-S and outcomes, results were presented as odds ratios (OR) and 95% confidence interval (CI), adjusted for pre-specified confounders. Background: Due to an increasing number and an earlier use of effective disease modifying anti-rheumatic drug (DMARD) therapy a growing number of rheumatoid arthritis (RA) patients reaches a state of clinical remission of disease. Whether clinical remission completely protects from structural bone damage, however, is still a matter of debate as conventional radiographic methods have their limitation in the sensitivity to characterize bone damage. Furthermore, residual activity of inflammation associated with the generation of inflammatory markers may characterize a subset of RA patients in remission, associated with higher prevalence and/or progression of bone damage. Objectives: To test whether residual systemic inflammation is associated with structural bone damage and the progression of structural bone damage in RA patients in sustained remission. Methods: RA patients (i) fulfilling the 2010 EULAR/ACR classification criteria of RA, (ii) having a positive anti-citrullinated protein antibody (ACPA) status and (iii) being in DAS28-ESR remission for 6 months were included. High-resolution peripheral quantitative computed tomography (HR-pQCT) of the right hand was done at baseline and after 1year. Erosion numbers and erosion volumes were assessed in the metacarpophalangeal joints. Vectra-DA tests measuring the serum levels of twelve different inflammation markers (CRP, SAA, IL-6, TNFR1, MMP-1, MMP-3, EGF, VEGF-A, VCAM-1, YKL-40, leptin and resistin) were performed in the baseline samples. MBDA score was calculated according to previously defined algorithms with low MDBA score defined as <30 units and moderate to high scores as ≥30 units (1). Results: 100 ACPA+ RA patients in sustained remission were investigate (mean±SD age: 57±14 ys; disease duration: 4.8±4.9 ys; DAS28: 1.7±0.5;63% females; 100% MTX treatment, 38% MTX+TNFi treatment). 65 patients had low (<30), 25 patients has moderate (≥30-44 and 10 patients had high (>44) MBDA scores. Patients in the different MBDA categories had similar age, sex, disease duration, DAS28 scores and DMARD treatment. Baseline HR-pQCT analysis showed that erosion numbers and volumes were significantly (p<0.001) higher in patients with high MBDA scores. Higher erosion numbers (>10) and larger erosions (>10 mm 3 ) were exclusively found in patients with moderate to high MBDA scores. MBDA scores were correlated to erosion numbers (p<0.001) and volumes (p=0.0018). Longitudinal analysis showed significant progression of erosions only in patients with high MBDA scores. Furthermore, progression (>5mm 3 increase in volume) over 1 year was confined to methotrexate treated patients, while tumor necrosis factor inhibitor treated patients were protected from progression even in case of moderate to high MBDA scores. However there were only 4 patients treated with TNFi that had a high MBDA score. Conclusions: These data show that residual disease activity assessed by MBDA score is associated with structural damage and progression of structural damage in RA patients in sustained remission. 
